INTRODUCTION

General introduction
The BMP family of ligands has been shown to play a role in a multitude of processes throughout the body, in particular in cellular lineage commitment, morphogenesis and patterning, differentiation, proliferation, cellular maintenance and survival. [1] [2] [3] Also in multiple myeloma, BMP signaling has been proposed to influence important processes such as growth control, bone homeostasis, iron metabolism and angiogenesis. However, BMP signaling is highly dependent on cell type and context. 
An introduction to bone morphogenetic proteins
Bone morphogenetic proteins (BMPs) constitute the largest subgroup of the transforming growth factor (TGF)-β family of ligands that also include growth and differentiation factors (GDFs), activins and nodal. The bone inducing activity of BMP was discovered in the 1960s and the first proteins of the family were characterized in the late 1980s. [5, 6] Further studies have revealed multiple functions for BMPs, such as involvement in embryogenesis, hematopoiesis and neurogenesis (reviewed by Bragdon et al.) , [2] as well as both tumor promoting and growth inhibiting effects in various cancers. [3] The signal is usually transduced through the (small) mothers against dpp (decapentaplegic) homolog (SMAD) pathway that is unique for the TGF-β family. [7] The pleiotropic effects of BMP suggest the need for tight control of its activities. This is achieved by multiple regulatory mechanisms, including regulation of ligand activity, availability of ligand, particularly regulated by highly specific antagonists, expression of receptors, decoy receptors, co-receptors and the inhibitory (I)-SMADs, SMAD6 and SMAD7. [2] 
BMP signal transduction
BMPs and other TGF-β family members signal by binding as active homo-, or sometimes, heterodimers to their respective serine/threonine kinase receptors. They either bind to a preformed receptor complex, or alternatively, a receptor complex is formed by ligand binding to high-affinity receptors followed by recruitment of receptors with lower affinity. For most BMPs this means initial binding to a type 2 receptor, followed by binding to a type 1 receptor. Upon ligand binding, the constitutively active type 2 receptor phosphorylates the type 1 receptor in the juxtamembrane glycine/serine rich domain (Figure 1 ). This activating step enables binding and phosphorylation of receptor activated (R)-SMADs. Which one of the RSMADs that is activated depends on the type 1 receptor and the composition of the receptor complex. In general, the R-SMADs are divided into two groups: (1) BMPactivated R-SMADs; SMAD1, SMAD5 and SMAD8 that are activated by ALK1, ALK2, ALK3 and ALK6. (2) TGF-β/Activin-activated R-SMADs; SMAD2 and SMAD3 that are activated by ALK4, ALK5 and ALK7. Activated R-SMADs bind the Co-SMAD, which in humans is SMAD4. Trimers consisting of SMAD4 and two R-SMADs translocate to the nucleus to repress or activate expression of SMAD-responsive genes. [2] The ligand-receptor interaction of the BMP/TGF-β family of ligands is highly promiscuous, as evident by the presence of only seven type 1 receptors and five type 2 receptors for over 30 different ligands. [3] Typically, one receptor can bind different ligands, whereas one ligand can activate different sets of receptors. Historically, one has thought that four type 1 receptors of the activin receptor-like kinases (ALK) are involved in BMP signaling. Thus, BMPs are believed to signal through ALK1, ALK2, ALK3, and ALK6, as well as through three type 2 receptors, namely BRII, ActRIIa, and ActRIIb (summarized in table 1). Now it has become clear that there is another level of complexity in that heteromeric receptor complexes exist that enables ligands to signal to both R-SMAD branches. Thus, TGF-β can activate heteromeric receptor complexes consisting of both ALK5 and ALK1, thereby activating both SMAD2/3 and SMAD1/5/8. [8, 9] Also, BMP-9 has been shown to induce phosphorylation of SMAD2 by signaling through ActRIIa in pulmonary endothelial cells. [10] More recently, it was shown that BMP-2 also could signal through heteromeric complexes consisting of TGFBR2/ALK5/ALK3, leading to SMAD2 phosphorylation, and BMPR2/ALK5/ALK3 or BMPRII/ALK7/ALK6 leading to Smad3 phosphorylation. [11] BMPs also share all type 2 receptors with activin A, which should be kept in mind when developing targeted therapies to these TGF-β family members. [3, 12] Additionally, TGF-β family type 3 receptors and coreceptors exist that contribute to regulation and fine-tuning of formation of the ligand-receptor complex. [13] The affinity of a single ligand to a single receptor will thus be of less importance than the affinity of a given ligand to the complete receptor-signaling complex, including coreceptors. Receptor expression will vary between cell types, the state of the cells and the microenvironment in which they reside.
Non-SMAD signaling pathways
Besides signaling through the canonical SMAD pathway, receptors of the TGF-beta superfamily may activate mitogen-associated protein kinases (MAPKs) p38, Jun Nterminal kinase (JNK) and extracellular signal-regulated kinase (ERK), the PI3 kinase-AKT-mTOR pathway and nuclear factor kappa beta (NFkB). [2] The focus of this review, however, is on the SMAD signaling pathway.
TGF-β/BMP induced growth arrest
TGF-β/BMPs potently induce cell cycle arrest in the G1 phase, but the mechanism varies between cell types. Here, a simplified version of the TGF-β/BMP induced cytostatic response is presented. MYC promotes cell proliferation and growth and TGF-β induced downregulation of MYC is a key event in this cytostatic process that was discovered over 20 years ago. [14] Cell cycle progression from G1 to S phase is dependent on the activity of cyclin-dependent kinases (CDKs). CDKN2B and CDKN1A, encoding the CDK inhibitors p15 and p21, are suppressed by MYC. MYC inhibits MYC-interacting zinc finger 1 (MIZ1) mediated activation of CDKN2B and CDKN1A. Thus, downregulation of MYC is necessary for their induction. [15, 16] CDC25A is involved in cell cycle progression by dephosphorylating and activating CDKs. Downregulation of CDC25A also seems to be important for the TGF-β/BMP cytostatic response. The inhibitor of DNA binding (ID) proteins are also involved in the cytostatic response although it is not entirely clear how. The ID proteins (ID1, ID2 and ID3) are transcriptionally downregulated by TGF-β activated SMADs, whereas BMP upregulates their transcription. [17] This might explain the fact that BMP exerts a much weaker growth-inhibitory effect on epithelial cells than TGF-β, in spite of higher induction of CDKN1A. [18] 
TGF-β/BMP induced apoptosis
The mechanism for TGF-β/BMP induced apoptosis varies between cell types. The TRAF6-TAK1-JNK/p38 pathway is essential in TGF-β induced apoptosis in prostate cancer cells. [19] This pathway also depends on SMAD7 as a scaffolding protein, enabling activation of p38. [20] R-SMAD-dependent pathways are also involved in apoptosis and one important regulator of apoptosis, the tumor suppressor gene Other mechanisms by which I-SMADs regulate SMAD signaling include prevention of R-SMAD/SMAD4 heteromerization by binding to SMAD4, recruitment of SMURFs to receptors leading to receptor degradation, and direct inhibition of transcriptional responses. [27] SMAD7 inhibits both TGF-β and BMP signaling, whereas SMAD6 mainly inhibits BMP signaling, and more efficiently signaling by ALK3/6 than ALK1/2. [29] BMP signaling is also regulated by phosphatases that dephosphorylate C-terminal phosphorylated R-SMADs. [27] Other intracellular regulatory mechanisms also exist, but will not be discussed here.
BMPS IN MULTIPLE MYELOMA
Expression of components of the BMP signaling pathway
Myeloma cells in general express all known BMP receptors except ALK1 (ACVRL1), which is predominantly expressed by endothelial cells. [30] [31] [32] [33] [34] ALK6 (BMPR1B) is variably expressed. [31, 35] The SMADs -1, -4 and -5 are also expressed, but not SMAD8. [33] Expression of mRNA encoding the ligands BMP-6 and -4 has been found to be increased in plasma cells from multiple myeloma patients compared to healthy individuals. [31, 33] Normal bone marrow stromal cells (BMSC) that have been passaged in cell culture have been shown to express BMP mRNA and protein. [36, 37] In supernatants of human myeloma cell lines and in BM plasma, low levels of BMP-6 were found using ELISA. [33] Another study found more BMP-2 in sera from multiple myeloma patients than in normal sera, but still at low levels (~ 60 pg/mL). [38] We found increased levels of BMP-9 in myeloma sera compared to normal sera. [35] However, the total BMP-activity in the bone marrow niche of multiple myeloma patients, as measured by in situ SMAD1/5/8-phosphorylation, is not known.
Expression of related receptors and ligands
Due to extensive sharing of receptors and possible heterogeneity of assembled ligand-receptor signaling complexes, expression of related TGF-β superfamily receptors and ligands is highly relevant. ALK5 (TGFBR1) is expressed in myeloma cells and is capable of being activated in response to TGF-β. [39] Both myeloma cell lines and primary cells were shown to express TGF-β mRNA and active protein, [40, 41] however it was also reported that myeloma cells do not produce active TGF- Expression of the other type 3 receptor, endoglin, is induced by TGF-β and hypoxia, [44, 45] and increased levels of soluble endoglin in myeloma patients were associated with advanced disease and tumor growth. [46, 47] Membrane-bound endoglin is found on some myeloma cell lines, but lack on others. [35] Expression of selected receptors and their putative ligands in myeloma cells is summarized in Table   1 .
Myeloma cell growth suppression by BMP
Only a few cytokines have been shown to inhibit myeloma cell growth, including BMP-2, -4, -5, -6, -7, and -9. [30, 33, 35, [48] [49] [50] 
Effects of other TGF-β family members on myeloma cell growth
Mutations in the TGF-β signaling pathway are not common in hematological cancers. [61] Abundant TGF-β in the areas of destructive bone lesions in bone marrow may contribute to suppression of bone formation in myeloma patients. [45] TGF-β has been shown to induce production and secretion of IL-6 and vascular endothelial growth factor (VEGF) by BMSC and myeloma cells, contributing to increased proliferation and survival of the malignant cells. [40, 62] TGF-β does not induce growth arrest in myeloma cells in vitro. [40] This could be explained by disturbed localization or trafficking of TGF-β receptors. [63] Another explanation may be that the cyclin dependent kinases (CDK) CDK2 and CDK4 can phosphorylate SMAD2/3, thereby inhibiting transactivation of genes. [64] In primary bone marrow myeloma cells SMAD2 was phosphorylated by CDK2 and the transcriptional regulation by TGF-β was disrupted. 
Modulation of BMP-signaling by TGF-beta family members
BMP and bone disease in multiple myeloma
Myeloma cells in the bone marrow usually proliferate slowly and have the capability to influence bone cells, causing both osteolytic lesions and systemic osteoporosis.
Thus, BMPs were initially discovered by their ability to induce bone formation.
Numerous in vitro and in vivo studies have shown that BMPs have osteogenic effects. Moreover, overactive signaling by BMP receptors may cause severe diseases with increased bone formation, such as fibrodysplasia ossificans progressiva (FOP). [69] Factors in bone marrow that are known to be elevated in multiple myeloma, such as hepatocyte growth factor (HGF) and dickkopf-1 (DKK-1), may inhibit the osteoinductive effects of BMPs. [70, 71] HGF was found to inhibit BMP-induced osteoblast differentiation of human mesenchymal stem cells. [72] This effect was partly explained by the fact that HGF abrogated nuclear translocation of BMP-activated R-SMADs. In contrast, HGF was found to induce the expression of BMP-2 in human osteoblast-like cells, in part by activating Runx2. [73] Autocrine Wnt signaling is necessary to promote BMP-2 induced differentiation in preosteoblasts. [74] Expression of the Wnt inhibitor DKK-1 correlated with lytic bone disease in MM and DKK-1 antagonized BMP induced osteoblast differentiation. [74] Sclerostin also antagonized BMP and/or Wnt activity, although the mechanism is not clear. [75] Recombinant sclerostin was proposed to antagonize the growth inhibitory effect of BMP-6 on a myeloma cell line in vitro, but the specificity was not entirely clear from this assay. [33] Sclerostin is expressed by osteocytes but can also be expressed by myeloma cells and high serum levels in myeloma patients correlated with advanced disease stage. [76, 77] Another Wnt inhibitor, sFRP-2, is secreted by myeloma cells and suppresses bone formation. [78] Myeloma cells may secrete interleukin (IL)-3, and IL-3 from the bone marrow plasma of myeloma patients inhibited both basal and BMP-2 induced osteoblast formation. [79] IL-3's bone remodeling effects were shown to depend on increased activin A secretion from CD14 + bone marrow monocytes. [80] Activin A levels were increased in bone marrow plasma of myeloma patients with osteolytic disease and has been proposed to play an important role in myeloma bone disease, at least in part by inhibiting phosphorylation of SMAD1/5/8 during osteoblastogenesis. [81, 82] Lenalidomide treatment has been shown to cause activin A secretion by myeloma BMSC, providing a rationale for a combination treatment of lenalidomide with activin A inhibition. [83] TGF-β is abundant in the bone marrow of myeloma patients, and represses bone formation in osteolytic lesions. At first, TGF-β induces expansion of osteoblast progenitors and promotes bone mineralization. What happens next is that TGF-β inhibits osteoblast differentiation and matrix mineralization, making TGF-β a possible target for therapy of myeloma bone disease. [45] 
BMP and hepcidin-related anemia in multiple myeloma
In MM, the most common cause of anemia is the anemia of chronic inflammation characterized by hypoferremia, normal to increased ferritin levels, and reduced saturation of transferrin. Hepcidin has been described as the principal iron-regulating hormone and is encoded by the gene HAMP. [84] BMP-2, -4, -6, and -9 all stimulated HAMP promoter activity in vitro whereas TGF-beta did not. [38] Thus, the conclusion drawn from this work was that BMP-2 was the main mediator of hepcidin induction in sera from myeloma patients. Targeting BMP-2 or other BMPs with the intention to treat anemia of multiple myeloma may not be a good approach, considering that there is substantial redundancy in the system regulating hepcidin. To counteract hepcidin induction other factors may have to be targeted simultaneously. Also, interfering with the positive effects induced by BMPs on inhibition of myeloma cell growth and promotion of bone formation could give unwanted side-effects. Therefore, a better way of treating anemia in multiple myeloma would be to target hepcidin itself.
THERAPEUTIC TARGETING OF THE BMP SIGNALING PATHWAY
Recombinant human BMP
BMP-2 and BMP-7 have been used in preclinical and clinical studies of different scenarios of bone regeneration including non-union, bone defects, open tibial fractures and spinal fusion (reviewed in Nauth et al.) . [85] The only reports found on use of BMPs in myeloma patients were two case-reports with use of rhBMP-2. The first report describes a patient that experienced induction of heterotopic bone formation after spinal fusion surgery. [86] The other report describes a patient initially not diagnosed with myeloma, where the disease exacerbated after lateral lumbar interbody fusion supplemented with BMP-2. [87] Despite good effects on bone formation, there are concerns that BMP treatment may have adverse effects such as seroma formation, neurologic deficits and heterotopic induction of bone. [88] Moreover, the potential roles of use of recombinant BMPs in neoplasia are not fully understood.
Ligand traps
The activin ligand trap Sotatercept (ACE-011; Celgene/Acceleron Pharma) is a fusion product of the extracellular domain of activin receptor type IIA (ActRIIA) and an IgG- 
CONCLUDING REMARKS
By their involvement in a number of processes in development and cancer, and adding the complexity of their regulation and modes of signaling, BMPs are difficult to control in a specific manner. We have here reviewed the roles of BMPs in the hematological malignancy multiple myeloma with regards to inhibition of cancer cell growth, osteolytic bone disease and hepcidin-related anemia. It would be of interest to investigate the in situ situation in the bone marrow of myeloma patients with regards to SMAD1/5/8 activation. In vitro studies suggest that it could be of advantage to try to increase bone marrow BMP activity in multiple myeloma.
Relevant in vivo studies on this are however needed to prove this concept. It should also be noted that many attempts to treat cancer by manipulating TGF-β/BMPsignaling are focused on inhibition of signaling, whereas in myeloma an opposite effect could be of greater benefit. Thus, in multiple myeloma there is a chance that by increasing BMP activity one could kill two birds with one stone; namely eradicate myeloma cells and counteract bone disease. Growth arrest 
